Revive Therapeutics (RVV.V) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19.
Today, Revive Therapeutics announced that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo. The Company expects to have New Bucillamine ready for clinical evaluation in 2024.
The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.
“We are now entering into the next phase of development with our next-generation lyophilized formulation of Bucillamine that has the potential to treat unmet medical needs and public health medical emergencies, and we expect to evaluate it in a clinical study this year,” said Michael Frank, CEO of Revive.
Key research findings and observations include:
- Lyophilization of Bucillamine enhances solubility 2.7x compared to standard solution of Bucillamine;
- Inclusion of lyophilization in the Bucillamine formulation approach can result in an ability to increase Bucillamine delivery per dosing unit; and
- Inclusion of lyophilization in the Bucillamine formulation approach offers a simple way to create a parenteral injection product with minimal formulation additives.
Revive will work with Attwill Medical Solutions LP in the technology transfer and prepare plans for potential clinical and commercial development in support of specific initiatives that the Company is involved with, such as the continuation of the research project the Company has with the Defence R&D Canada – Suffield, an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.
Additionally, Revive may explore the New Bucillamine as a potent antioxidant and anti-inflammatory, for rare inflammatory disorders such as ischemia-reperfusion injury which the FDA granted orphan drug designation for in 2022.
A classic range pattern.
The stock is testing its major support zone around $0.025. The stock should see buyers enter here to hold support. A daily close above $0.04 would be a good start for potential upwards momentum. The major resistance zone comes in at the $0.06 zone.
On November 20th 2023, bulls stepped in and printed a strong full bodied engulfing candle. This is a strong sign that buyers are here. If you look to July and August 2023, you can see that engulfing candles have led to bounces back to the $0.06 resistance zone.
So far a good start holding support and investors and market participants should watch for that break above $0.04.
